Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$15.15 - $19.78 $1,378 - $1,799
-91 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$16.86 - $19.67 $150,239 - $175,279
-8,911 Reduced 98.99%
91 $2,000
Q3 2020

Nov 16, 2020

BUY
$15.4 - $20.16 $137,137 - $179,524
8,905 Added 9180.41%
9,002 $157,000
Q2 2020

Aug 14, 2020

SELL
$18.24 - $21.45 $2,444 - $2,874
-134 Reduced 58.01%
97 $2,000
Q1 2020

May 15, 2020

SELL
$16.28 - $25.63 $258,412 - $406,824
-15,873 Reduced 98.57%
231 $5,000
Q4 2019

Feb 14, 2020

SELL
$19.57 - $23.52 $176 Million - $211 Million
-8,982,174 Reduced 99.82%
16,104 $375,000
Q3 2019

Nov 14, 2019

SELL
$19.85 - $22.76 $165 Million - $190 Million
-8,334,992 Reduced 48.09%
8,998,278 $180 Million
Q2 2019

Aug 14, 2019

SELL
$17.59 - $21.1 $6.88 Million - $8.25 Million
-391,022 Reduced 2.21%
17,333,270 $366 Million
Q1 2019

May 15, 2019

BUY
$18.01 - $20.11 $8.69 Million - $9.71 Million
482,715 Added 2.8%
17,724,292 $356 Million
Q4 2018

Feb 14, 2019

BUY
$17.44 - $21.53 $9.08 Million - $11.2 Million
520,797 Added 3.11%
17,241,577 $317 Million
Q3 2018

Nov 14, 2018

BUY
$19.97 - $21.96 $4.32 Million - $4.75 Million
216,289 Added 1.31%
16,720,780 $357 Million
Q2 2018

Aug 14, 2018

BUY
$20.16 - $24.68 $7.44 Million - $9.1 Million
368,913 Added 2.29%
16,504,491 $355 Million
Q1 2018

May 14, 2018

BUY
$20.31 - $24.95 $7.16 Million - $8.8 Million
352,590 Added 2.23%
16,135,578 $342 Million
Q4 2017

Feb 12, 2018

SELL
$20.99 - $23.89 $602,811 - $686,096
-28,719 Reduced 0.18%
15,782,988 $362 Million
Q3 2017

Nov 14, 2017

SELL
$20.07 - $21.89 $1.48 Billion - $1.61 Billion
-73,750,007 Reduced 82.35%
15,811,707 $346 Million
Q3 2017

Nov 13, 2017

BUY
$20.07 - $21.89 $1.8 Billion - $1.96 Billion
89,561,714
89,561,714 $272 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.33B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Harding Loevner LP Portfolio

Follow Harding Loevner LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

News

Stay updated on Harding Loevner LP with notifications on news.